Bayer AG (BAYN:XETR) experienced a significant drop in its share value, hitting a 20-year low, after projecting a further decline in earnings for 2025 due to persistently weak agricultural markets. Last week, the German conglomerate's shares fell 11.6% to €21.57 by mid-morning as it continues to grapple with challenges across its diverse sectors.
Chief Executive Bill Anderson has been proactive in restructuring the company by cutting jobs, streamlining decision-making processes, and reducing bureaucratic hurdles, with an aim to revitalize the faltering industrial giant. However, despite holding off on plans to break up its various business units, investor confidence appears shaky.
Anderson remains optimistic about Bayer's future, highlighting promising developments in the pharmaceutical sector, such as the successful launches of Nubeqa for prostate cancer and Kerendia for kidney disease. Nonetheless, the agricultural downturn remains a significant concern, exacerbated by a muted earnings outlook for the coming year.
Criticism from shareholders has intensified, with calls for clearer communication on medium-term financial targets to restore trust. Markus Manns, a portfolio manager at Union Investment, emphasized the urgent need for Bayer to accelerate its transformation and articulate a clear, sustainable growth strategy focusing on sales, earnings, and debt reduction.
